Kyoritsu Holding and Tencent were among the investors that backed the pet antibody therapeutics developer, a spinout of Wellcome Sanger Institute.

UK-based pet-focused antibody treatment developer PetMedix closed a £27m ($37m) series B round today that included pharmaceutical and veterinary group Kyoritsu Holding and internet group Tencent.

Cambridge Innovation Capital, a vehicle formed by University of Cambridge, also took part in the round, as did venture capital firm Digitalis Ventures and spinout-focused investment firm Parkwalk Advisors.

Spun out of University of Cambridge-affiliated genetics research organisation Wellcome Sanger Institute in 2018, PetMedix is developing veterinary antibody therapies targeting medical conditions in dogs…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn